Role of Acarbose in Glycemic Control. by Sheena Marin, Thomas
  
 
                  ROLE OF ACARBOSE IN GLYCEMIC CONTROL 
 
 
 
Dissertation Submitted to 
The TamilNadu Dr. M.G.R.Medical university, Chennai 
In partial fulfillment for the degree of  
MASTER OF PHARMACY 
(PHARMACY PRACTICE) 
APRIL 2012 
Submitted by 
SHEENA MARIN THOMAS 
(26107289) 
 
Under the Guidance of  
Mrs. K. GEETHA, M.pharm., (Ph.D.,) 
 
DEPARTMENT OF PHARMACY PRACTICE 
                          KMCH COLLEGE OF PHARMACY 
                               KOVAI ESTATE, KALAPATTI ROAD                 
                                             COIMBATORE-641048 
 
  
 
 
 
Dr.A.RAJASEKARAN, M.Pharm., Ph.D., 
Principal, 
KMCH College of pharmacy,   
Kovai Estate, Kalappatti Road, 
Coimbatore – 641 048.  
 
                                                       
                                             
 
                                   CERTIFICATE 
 
            This is to certify that the dissertation  work entitled “ROLE OF ACARBOSE 
IN GLYCEMIC CONTROL” was carried out by Sheena Marin Thomas. The 
work mentioned in the dissertation was carried out at the Department of Pharmacy 
Practice, KMCH College of Pharmacy, Coimbatore – 641 048, under the guidance of   
Mrs K Geetha, M. Pharm., (Ph.D.,) for the partial fulfillment for the Degree of 
Master of Pharmacy in Pharmacy Practice during the academic year 2011-2012 
and is forwarded to The Tamil Nadu Dr.M.G.R. Medical  University, Chennai. 
 
 
 
Dr. A. RAJASEKARAN, M.Pharm., Ph.D., 
 
Principal 
 
 
  
 
 
 
Mrs K GEETHA, M.Pharm., (Ph.D.,) 
Department of Pharmacy Practice, 
KMCH College of Pharmacy, 
Kovai Estate, Kalappatti Road, 
Coimbatore – 641 048.  
 
 
CERTIFICATE 
 
            This is to certify  that the dissertation work entitled “ROLE OF ACARBOSE 
IN GLYCEMIC CONTROL” submitted by Sheena Marin Thomas to the Tamil 
Nadu Dr.M.G.R.Medical University, Chennai, in partial fulfillment for the Degree of 
Master of pharmacy in Pharmacy Practice is a bonafide work carried out by the 
candidate under my guidance at the Department of Pharmacy Practice, KMCH 
College of Pharmacy, Coimbatore, during the year 2011 – 2012. 
 
 
          
 
 Mrs. K. GEETHA, M. PHARM. , (Ph.D.,) 
 
                                                                              Department of Pharmacy Practice 
   
 
 
  
 
 
 
 
DECLARATION 
 
           I do  hereby declare that the dissertation work entitled “ROLE OF 
ACARBOSE IN GLYCEMIC CONTROL” submitted to the Tamil Nadu 
Dr.M.G.R. Medical University, Chennai ,in  partial  fulfillment   for   the   Degree  of   
Master of Pharmacy in  Pharmacy  Practice,  was  done under  the guidance  of  
Mrs K Geetha,  M pharm., (Ph.D.,) at the department of Pharmacy Practice, KMCH 
College of Pharmacy, Coimbatore, during the academic year  2011-2012 
 
 
 
 
 
 
Sheena Marin Thomas 
  
 
 
 
  
 
 
EVALUATION CERTIFICATE 
 
This is to certify that the  dissertation work entitled “ROLE OF ACARBOSE  
IN GLYCEMIC CONTROL” submitted by Sheena Marin Thomas, University  
Reg No: 26107289 to  the Tamil  Nadu Dr.M.G.R. Medical  University,  Chennai, in  
partial  fulfillment  for  the  Degree of  Master of Pharmacy in Pharmacy Practice  
is a  bonafide work  carried out  by  the candidate at the Department of Pharmacy  
Practice, KMCH College of Pharmacy, Coimbatore  and  was  evaluated by  us  
during  the  academic   year  2011-2012. 
 
 
 
Examination Center:   KMCH College of Pharmacy, Coimbatore   
Date: 
 
 
 
Internal Examiner                                                                        External Examiner 
 
 
 
Convener of Examination 
  
 
                              
         
Dedicated to God 
Almighty  
&  
My Parents  
  
 
 
 
 
 
 
          
         Acknowledgement 
 
 
 
 
 
 
 
 
  
 
ACKNOWLEDGEMENT 
 
    First and foremost I am extremely beholden to the Almighty God   for the grace and 
mercy follows me all through my life much more than I rightfully deserve 
 
    It gives me great pleasure to record my deep sense of gratitude and indebtedness to 
my esteemed guide Mrs K Geetha, M.Pharm., (Ph.D.,) for her constant insight, 
guidance, countless serenity, encouragement and painstaking efforts in my project 
work. I am indebted to her kindness and never failing co-operation. 
 I extend my gratitude to Dr.A.RAJASEKARAN, M.Pharm., Ph.D., Principal, 
KMCH College of pharmacy, Coimbatore, for his constant encouragement, support and 
facilities provided.  
I extend my sincere thanks to our beloved chairman Dr. Nalla G.  
Palaniswamy  MD., AB (USA)., and  Madam  Trustee Dr.Thavamani  D  
Palanisami, MD., Of  Kovai  Medical  Centre  Research  and  Educational  Trust, 
Coimbatore  for  providing  me  with  all  the  necessary  facilities  to  carry  out  a  
work  of  this  kind  in  a  corporate  hospital. 
 
I offer my heartfelt thanks to Dr. Mrs. Suchandra Sen., M.Pharm., Ph.D., 
Head of the Department of Pharmacy Practice, for her suggestions and encouraging 
words. Her simplicity and caring attitude will be cherished in all walks of my life. 
I express my heartfelt thanks to Mr. A Vijayakumar M. Pharm., (Ph.D.,), 
Department of Pharmacy Practice for his expert managerial skills, assertiveness, 
motivation, valuable suggestions and support to this study. 
  
 
      My heartfelt thanks to my lecturers, Mr. V. Shiva Kumar M.Pharm., (Ph.D),  
Mr. K. Chandrasekaran, M.Pharm., Mr. C. Dhandapani, M.Pharm, Mr. 
Palanisamy, M.Pharm., (Ph.D) and all other  teaching  and  non-teaching  staffs  for  
their encouraging  suggestions  and judicious  help. 
 
It is my long felt desire to express our heartiest gratitude to Dr. Sivagnanam, 
MBBS, D.Diab, Consultant Diabetologist, KMCH. It is a matter of fact that without 
his kind cooperation this work could not be achieved successfully. 
I  take  this  opportunity  to  acknowledge  the  help  extended  to  me  by the 
Medical Records Department of KMCH, without whose  timely  assistance, the data  
collection  would   not  have  been  possible. 
 
It gives me intense pleasure to dedicate my project work to my loving parents, 
Mr C. M Thomas, Mrs Susamma Thomas whose blessings and aspirations always 
inspired me. I express my warm admiration to my loving brother Mr Shijo Thomas 
and his wife Mrs Lincy Sam and to my neice Steffy for their constant help and moral 
support. 
. I would like to mention a special sense of gratitude to my friends Mr. Bijoy 
Cherian, Ms. Feba Baby for their help throughout the study. 
 
It’s my privilege to express my deep sense of gratitude and love to all my dear 
classmates and juniors for their timely help and co-operation 
                                                                                     
                                                                                       Sheena Marin Thomas 
 
  
 
 
 
 
 
 
 
Abbreviations 
 
 
 
 
 
 
 
 
 
 
  
 
 
 ABBREVIATIONS 
 
ADA   -  American Diabetes Association 
UKPDS  -          United Kingdom Prospective Diabetes Study 
DCCT   -          Diabetes Control And Complications Trial 
DM    -  Diabetes Mellitus 
BP   -  Blood Pressure 
PVD    -  Peripheral vascular disease 
NIDDM   -  Non Insulin Dependent Diabetes Mellitus 
DIS    -  Diabetes Intervention Study 
FBS    -  Fasting Blood Sugar  
PPBS    -  Post Prandial Blood Sugar 
HbA1C     -  Glycosylated Haemoglobin 
IGT    -  Impaired Glucose Tolerance 
MI    -  Myocardial Infarction 
HDL         -  High Density Lipoprotein 
LADA    -  Latent Autoimmune Diabetes in Adults 
BMI                   -         Body Mass Index 
mg    -   milligram 
dl                       -          decilitre 
OHA    -          Oral Hypoglycemic Agent 
AGIs                 -           Alpha Glucosidase Inhibitors 
S.D               -   Standard Deviation            
  
 
 
                                              
                                       
 
 
 
 
Index 
 
 
 
 
 
 
 
 
 
 
 
  
 
INDEX 
S.No CONTENTS PAGE No 
 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
 
INTRODUCTION 
REVIEW OF LITERATURE 
PLAN OF THE STUDY 
OVERVIEW 
METHODOLOGY 
TABLES AND GRAPHS  
RESULTS 
DISCUSSION 
CONCLUSION 
BIBLIOGRAPHY 
ANNEXURES                
Annexure 1: Patient data collection form 
 
1 
7 
17 
18 
26 
28 
45 
49 
53 
55 
 
 
 
 
 
 
 
                                     
 
  
 
                                             
ABSTRACT 
 
The prevalence of Type II diabetes is rising rapidly worldwide with Africa and Asia 
having the greatest potential increases. Acarbose an α-glucosidase inhibitor, acts 
specifically at the level of postprandial glucose excursion. Its used in combination 
with oral hypoglycemics and insulin. The aim of the study was to evaluate the 
efficacy of Acarbose in improving the glycemic control in Type II diabetic patients. 
This prospective study conducted on 74 Type II Diabetic patients included both male 
and female patients having HbA1C value above 6.5%. Among 74 patients 40 patients 
were on Acarbose therapy and 34 patients were in another group taking oral 
hypoglycemics other than Acarbose. Its efficacy in obese and non obese type II 
diabetic patients and the percentage reduction in blood glucose values were done. Its 
effect in reducing the PPBS and HbA1C values were found to be higher in obese 
patients than non obese patients. The p value of PPBS and HbA1C in obese patients 
were found to be (p=0.0006) and (p<0.0001). Similarly patients on Acarbose therapy 
showed a significant reduction in blood glucose values than patients on oral 
hypoglycemic agents alone. It is associated with improvement in glycemic parameters 
and was safe and well tolerated. After a period of three months when the patients 
came for the first review it has been found that patients taking Acarbose with oral 
hypoglycemic agents and Insulin therapy showed 18.8% reduction in FBS, 16.82% 
reduction in PPBS and 17.92% reduction in HbA1C. Thus it was concluded that 
Acarbose represents a new approach to the management of NIDDM, modulating 
gastrointestinal carbohydrate metabolism to control postprandial hyperglycemia and 
to maximize long-term glycemic control.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
  
 
INTRODUCTION 
Diabetes mellitus is one of the most common endocrine disorders affecting almost 6% 
of the world’s population, with the majority having Type II diabetes. The global 
prevalence of diabetes is estimated to rise substantially, with an accompanying 
increase in diabetes-related morbidity and mortality. It predisposes individuals to 
vascular, renal, ophthalmic and neurological complications and is a major risk factor 
for cardiovascular disease.1 It is most commonly due to autoimmune Type I diabetes 
or to adult-onset Type II diabetes. Insufficiency of insulin affects the metabolism of 
carbohydrate, protein and fat which can cause a significant disturbance of water and 
electrolyte homeostasis2 
 
Type I Diabetes Mellitus 
It results from immune mediated destruction of the β cells of the pancreas which 
results in absolute insulin deficiency. About 5 to 10% of people with diabetes have 
type1 disease.3 It usually occurs in children and adolescents but it can affect at any 
age. Younger individuals have a rapid rate of β-cell destruction and have ketoacidosis, 
for many years adults maintain sufficient insulin secretion to prevent ketoacidosis, 
which is often referred to as LADA4 
 
 
Type II Diabetes Mellitus: 
It is a chronic disease, resulting from interplay between genetic and environmental 
factors and characterised by hyperglycaemia. It is associated with the development of 
microvascular complications, such as retinopathy, neuropathy and nephropathy, and 
of macrovascular complications, which increase the risk of cardiovascular events.5  
             
  
 
 There is an abundance of evidence showing that good glycemic control reduces the risk 
of microvascular damage. Intensive glucose control significantly reduced the risk of 
microvascular complications.6 Obesity is a disorder and it results from a complex 
interplay of environmental and genetic factors which is associated with significant 
morbidity and mortality. Thus the afflicted suffer emotional consequences from social 
stigmatization and consequently have an increased risk of many medical disorders.7 
  
The prevalence and incidence of Type II diabetes is rising rapidly worldwide with 
Africa and Asia having the greatest potential increases. Lifestyle changes in Asia 
resulting from urbanization and industrial development have triggered epidemic rises 
in type 2 diabetes. The UK Prospective Diabetes Study has shown that intensive blood 
glucose control is essential for reducing the risk of developing diabetes sequelae .8 
 Type 1 treatment necessitates Insulin therapy. Treatment of Type II often necessitates 
use of multiple therapeutic agents including oral antihyperglycemics and insulin to 
obtain glycemic goals.9  The different prevention strategies for type 2 DM are lifestyle 
changes, dietary restriction of fat, aerobic exercise and weight loss form the backbone 
of successful prevention.10 
 
 In addition, in the long term majority of patients need multiple therapies to attain 
these glycemic target levels. Even with Sulfonylurea and Metformin combination 
therapy, most patients end up with secondary failure and a third agent is needed to 
achieve HbA1C target values.11. Results of recent evidence-based clinical studies, 
acarbose, indicate that an α- glucosidase inhibitor, has a beneficial effect on glycemic 
control without weight gain effect in Type II diabetes mellitus.12 
  
  
 
The first step in evaluation of obesity is calculation of BMI. It is usually calculated by 
dividing weight (in kilograms) by square height (in meters). It correlates significantly 
with body fat, morbidity, and mortality and can be calculated quickly and easily.7 
Dietary measures, lifestyle changes, and oral therapy using Sulfonylureas, Biguanides 
or Insulin often do not achieve adequate results; monotherapy with antidiabetic 
agents, in particular, fails  to control blood glucose levels satisfactorily in the long-
term.13 The pseudo-tetrasaccharide Acarbose delays the digestion of complex 
carbohydrates and disaccharides by competitive α-glucosidase inhibition at the 
ciliated border of the small intestine.8 It has been estimated that 86% of those with 
type 2 diabetes are overweight or obese. It is associated with significantly worse 
cardiovascular risk factors in these patients.14 
 
Persisting hyperglycemia has been linked to the development of diabetic 
complications and to the exaggeration of insulin resistance and impaired insulin 
secretion that characterizes the pathophysiology of non-insulin-dependent diabetes 
mellitus.15 Diet therapy remains the cornerstone of the treatment strategies for non-
insulin-dependent diabetes mellitus; it is intended to achieve and maintain ideal body 
weight16 
 
 The secondary complications of diabetes are highly correlated with long-term control 
of blood glucose levels. The findings of the Diabetes Control and Complications Trial 
(DCCT), performed  by the American Diabetes Association, clearly demonstrate a 
close relationship between quality of glycemic control in insulin-dependent diabetes 
mellitus as indicated by HbA1C levels, and the incidence of diabetes-specific 
complications.17-18  In the 11-year follow-up of the diabetes intervention study (DIS) 
with newly detected NIDDM  postprandial hyperglycemia was an independent risk 
  
 
factor for both incidence of myocardial infarction and all-cause mortality. Perfect 
control of postprandial hyperglycemia, blood pressure, and triglycerides according to  
the target categories of the NIDDM study was associated with significantly fewer 
events.1 
α-Glucosidase Inhibitors  
α-Glucosidase  inhibitors (AGIs)  reduce intestinal absorption of starch, dextrin, and 
disaccharides by inhibiting the action of α-glucosidase in the intestinal brush 
border20, Inhibition of this enzyme slows the absorption of carbohydrates; the 
postprandial rise in plasma glucose is blunted in both normal and diabetic subjects.21 
Mainly three AGIs exist such as Acarbose, Miglitol and Voglibose Among the 
inhibitors it has been shown that Acarbose could prevent or delay the development 
of  IGT in Type 2 Diabetes. They usually have a decreasing effect on fasting and 
post load insulin levels compared to Sulphonyl Urea.22    
Titrating the dose of drug slowly (25 mg) at the start of a meal for 4 to 8 weeks, 
followed by increases at 4- to 8-week intervals to a maximum of (75 mg) before each 
meal reduces gastrointestinal side effects.23 It is most effective when given with a 
starchy, high-fiber diet with restricted amounts of glucose and sucrose. If 
hypoglycemia occurs when α-glucosidase inhibitors are used with insulin or an insulin 
secretagogue, glucose rather than sucrose, starch, or maltose should be administered.21   
They act by a reversible inhibition of alpha glucosidase which is an enzyme present in 
the brush border of small intestine. They delay the absorption of complex 
carbohydrates and thus inhibit post prandial glucose peaks band leads to decreased 
post prandial insulin levels22 
  
 
AGIs are widely used in the treatment of patients with type 2 diabetes. It usually delay 
the absorption of carbohydrates from the small intestine and have a lowering effect on 
postprandial blood glucose and insulin levels. They have clear beneficial effects on 
glycemic control and postload insulin levels but not on plasma lipids.24           
 Acarbose 
      
 Acarbose is an α-glucosidase inhibitor, acts specifically at the level of postprandial 
glucose excursion. In patients with type 2 diabetes, Acarbose is used as monotherapy 
and in combination with oral glucose-lowering agents and insulin. It is associated 
with improvement in glycemic parameters, and was safe and well tolerated.25    
 
It is a novel drug that attenuates postprandial hyperglycemia by delaying carbohydrate  
digestion, without causing major side effects. It   initiate a cascade of events, leading 
to improved metabolic control. The drug smoothes the glycemic curve and causes a 
reduction in postprandial blood glucose levels and hyperinsulinemia, reducing hepatic 
triglyceride biosynthesis. It also probably inhibits the development of insulin 
resistance. 26 
 
 It is an inhibitor of α-glucosidase and thus acts directly at the gastrointestinal level 
slowing down the intestinal absorption of glucose and reducing the rapid increase in 
glycemia induced by a meal rich in carbohydrates.27 The degree of improvement of 
fasting and postprandial glycemia is confirmed by the significant reduction of HbA1C. 
It is effective in reducing postprandial glycemia and glycosylated haemoglobin in 
patients normally treated with diet, with Sulphonyl Ureas, Metformin or Insulin.28 
 
  
 
 There is increasing epidemiological evidence for the association of PPBS levels and 
macrovascular complications in nondiabetic and diabetic individuals. A reduction of  
postprandial blood glucose levels by the Acarbose, delays glucose release from 
complex carbohydrates, and associated with a risk reduction of cardiovascular 
disease. Meta analysis of seven randomized, double-blind, placebo-controlled studies 
on the use of acarbose in diabetic patients indicated that acarbose treatment was 
associated with a 35% risk reduction of cardiovascular disease.5        
 
Its a complex oligosaccharide which reversibly inhibits α- glucosidase   present in the 
brush border of small intestinal mucosa. It slows down and decreases digestion and 
absorption of polysaccharides and sucrose and thus PPBS is reduced without 
increasing insulin levels. It’s a mild anti hyperglycemic and not a hypoglycemic and 
may be used as an adjuvant to diet in obese diabetics. Its minimally absorbed but 
produces flatulence and loose stool due to fermentation of unabsorbed 
carbohydrates.29 
The properties of Acarbose make this a promising agent for the treatment of patients 
presenting hyperglycemia, hyperinsulinemia and hypertension. Inhibition of α-
intestinal glucosidases retards the absorption of ingested carbohydrates and attenuates 
PPBS and hyperinsulinemia. A potential beneficial effect of the drug on insulin 
resistance due to the improvement in hyperglycemia and glucotoxicity may also 
contribute to reducing blood pressure (BP) in hypertensive diabetic patients.30 
 
 
 
 
  
 
 
 
 
 
 
 
 
Review of Literature 
 
 
 
 
 
 
 
 
 
 
 
  
 
REVIEW OF LITERATURE 
 
      TMS Wolever et al reported that long-term use of Acarbose therapy in subjects 
with NIDDM on weight-maintaining diets, may result in a small weight loss, but has 
no effect on energy or nutrient intakes. The weight loss induced may be due to reduced 
doses of concomitant oral agents and insulin and partly due to energy loss due to 
increased colonic fermentation.31 
 
  Boniface J Lin et al in their studies on Asian Type 2 diabetic patients concluded 
the possible benefits of adjunctive Acarbose therapy in addition to the use of diet and 
Sulfonylureas. It was significantly superior to placebo as observed in the reduction of  
primary efficacy parameter HbA1C. It reflects the long-term control of glycemic control 
and reduces risk of microvascular endpoints. A major problem using oral antidiabetic 
drugs such as Sulfonylureas is decreasing ability to control blood glucose levels 
satisfactorily. Acarbose acts as an antihyperglycemic agent and has the additional 
benefit of reducing weight gain.8 
        Gabriele Mertes concluded in his study that Acarbose was found to be generally 
well tolerated with a lower incidence of side effects than placebo-controlled studies. 
Patients showed marked improvements in a range of metabolic parameters over the 5-
year course of the study. It demonstrated its usefulness both as first-line monotherapy 
and as an important addition to other antidiabetic drugs for improving metabolic 
controls in patients with Type 2 diabetes. The majority of the patients were sufficiently 
treated with a low dose and proved to be a safe drug in a high risk patient population.32 
 
  
 
       Chii-Min Hwu et al discussed that acarbose offers advantages as a combination 
therapy with insulin in the treatment of Type II diabetes and works well in Asian 
diabetic patients. Owing to its particular mode of action, it improves the therapeutic 
efficacy of concomitant insulin without the risk of weight gain and hypoglycemia.33 
       Chunlin Li et al stated that Acarbose can be used as a first-line therapy or in 
combination with other glucose-lowering agents for type 2 DM and it was found to be 
associated with improvement in glycemic parameters, and was safe and well tolerated. 
In addition, it will  maintain glycemic control and a good tolerability profile over the 
long term in Type II diabetic patients.1 
 
     L. Sangiorgio et al suggested that addition of acarbose was found to be effective 
in improving glycemic control in overweight elderly Type II diabetic patients with 
poor glycemic control on OHA or insulin regimes. Acarbose is an inhibitor of α-
glucosidase and acts directly at the gastrointestinal level slowing down the intestinal 
absorption of glucose and eventually reduce the rapid increase in glycemia induced by 
a meal rich in carbohydrates.28 
 
        B.Brooks et al stated that after Acarbose therapy was initiated, patient improves 
glycemic control and changes post-prandial energy expenditure of Type II diabetic 
patients in secondary failure. The magnitude of long term reduction in hyperglycemia 
differs amongst individuals. This is largely due to intrinsic variations in patients’ 
response to Acarbose rather than differences in medication compliance or dietary 
composition.34 
        
  
 
        Jean-Louis Chiasson et al revealed that Acarbose improved long-term glycemic 
control in patients with non-insulin-dependent diabetes mellitus regardless of 
concomitant antidiabetic medications. Our study shows that it is a safe drug for treating 
patients with non-insulin-dependent diabetes mellitus. Over 1-year study period, 
acarbose did not affect hematologic, biochemical, or liver function test results. Our 
study also strongly suggests that the drug does not induce nutritional malabsorption 
because the serum concentrations of vitamins and minerals remained unchanged in 
patients treated with acarbose16 
 
M. Hanefeld et al examined that Intervention with acarbose can prevent 
myocardial infarction and cardiovascular disease in Type II diabetic patients while 
most of them are already on intensive concomitant cardiovascular medication. acarbose 
treatment of type 2 diabetes has shown preventive effects on myocardial infarction and 
any cardiovascular events. This may be explained by a reduction of postprandial 
hyperglycaemia and improvement in other features of the metabolic syndrome.35 
 
     Peter N Bavenholma et al reported that reduced ability to control blood glucose 
level results in postprandial hyperglycaemia, which affects the vascular endothelium 
and leads to the development of CVD. This impact may be attenuated by the use of  
Acarbose. The results from the STOP-NIDDM trial and the meta-analysis suggest that 
it can reduce the risk of CVD and support a scientific rationale for the early use of 
Acarbose to reduce the progression from IGT to established type 2  diabetes and to 
reduce the risk of CVD.36 
 
  
 
     Floris A Van de Laaar et al examined in their systematic review of 41 
randomized studies on the efficacy of AGIs, statistically significant effects on GHb 
and fasting blood glucose, post load glucose and insulin levels, and BMI has been 
found. There was no increase in effect on GHb for acarbose dosages higher than 50 
mg tid. In general, most evidence and the best results were found for acarbose. AGIs 
have clear beneficial effects on glycemic control and postload insulin levels but not 
on plasma lipids.7 
 
       Robert Coniff et al stated that Acarbose represents a new approach to the 
management of NIDDM, modulating gastrointestinal carbohydrate metabolism to 
control postprandial hyperglycemia and to maximize long-term glycemic control. It 
usually in doses of up to 100 mg three times daily for periods up to 16 weeks, was  
significantly superior to placebo with respect to the mean reduction in HbA1C levels 
and mean l-hour postprandial glucose levels.6 
 
       J M Ghosh examined that Acarbose when combined with modified diet resulted 
in significant decline in postprandial blood glucose in Type II DM cases, large 
majority of which were cases of secondary failure with oral hypoglycemic agents 
(OHA). It is suggested that before adding Insulin in cases of OHA failure, adequate 
trial of low G.I. diet and Acarbose should be routinely tried.37 
           
       Michio Shimabukuro et al suggested that Acarbose might reduce macrovascular 
complication by avoiding endothelial injury in postprandial hyperglycemic status. It 
might be a promising post prandial therapy in treating endothelial function seen in 
patients with type 2 diabetes mellitus by decreasing the postprandial glucose 
excursion. It was found that even a single loading of test meal was shown to impair 
  
 
endothelial function in type 2 diabetic patients, and the postprandial endothelial 
dysfunction was improved by a prior use of Acarbose.5 
             
      Uwe Zeymer examined that Acarbose is the first anti-diabetes agent that has been 
shown in a randomised, placebo-controlled trial to delay the progression of glucose 
intolerance to diabetes and reduce the risk of cardiovascular events. These attributes 
provide a strong rationale for the use of such agents to reduce cardiovascular risk in 
patients with impaired glucose control. The results of the STOP-NIDDM and the 
acarbose meta-analysis provide strong evidence that preventing postprandial 
hyperglycaemia reduces the risk of cardiovascular events in patients with impaired 
glucose tolerance and overt Type II diabetes.21 
       
         P. Rosenbaum et al reported Acarbose shows benefits in terms of the glycemic 
control of hypertensive diabetic patients previously treated with diet alone or 
combined with sulfonylurea. The administration of acarbose to sulfonylurea-treated 
patients may prevent weight gain. Such effects are desirable taking into account the 
elevated cardiovascular risk of these patients. Acarbose monotherapy or combined 
with sulfonylurea was effective in improving glycemic control in hypertensive 
diabetic patients. Acarbose induced improvement in metabolic control may reduce BP 
in these patients. 30 
        
        Markolf Hanefeld suggested that Acarbose is a drug with a novel mechanism of 
action, which attenuates postprandial hyperglycemia by delaying carbohydrate  
absorption. This is achieved by competitive inhibition of key intestinal enzymes. It 
has been shown to be an effective oral antidiabetic agent that improves glycemic 
control, producing HbA1C reductions of 0.6 to 2.5 percentage points. Good glycemic 
  
 
control is of major importance in trying   to prevent secondary diabetic complications 
and the   increased mortality in patients with NIDDM.26 
 
        Henrik Wagner et al stated that in subjects with mild type 2 diabetes, exercise 
training improved insulin sensitivity but had no effect on glycemic control. The addition 
of acarbose to exercise, however, was associated with significant improvement of 
glycemic control and possibly cardiovascular risk factors. When exercise training was 
combined with acarbose treatment a decrease in HbA1C level and fasting plasma glucose 
concentration was observed. Treatment with Acarbose alone was associated with 
improvement in blood pressure and β-cell function, as reflected by a significant 
decrease in plasma proinsulin level.38 
  
  Patrick Phillips et al suggested that Acarbose therapy have a beneficial effect in 
reducing the overall glycemic control in overweight patients insufficiently controlled 
by Metformin alone. HbA1c levels showed a clinically significant difference of 
1.02%  in acarbose patients after 24 weeks of treatment compared to placebo patients . 
The addition of acarbose to metformin monotherapy provides an efficacious and safe 
alternative for glycemic improvement in overweight type 2 patients inadequately 
controlled by metformin alone.25 
     
 Su Jian-bin et al stated that in patients with higher mean amplitude of glycemic  
excursions (MAGE), treatment with acarbose obviously decreases hypoglycemia,  
postprandial glycemia and total insulin used per day. It’s an α-glucosidase inhibitor  
  
 
and competitively inhibit the α-glucosidase and prevent it from hydrolyzing 
disaccharides to monosaccharides and leads to decrease peak blood glucose 
concentration after meal. Therefore total insulin used per day consequently reduced  
 with the decline of postprandial glycemia, and hypoglycemia. Combination therapy 
of premixed insulin twice daily with acarbose may be an effective and convenient 
treatment for patients.39 
 
 Chien- Wen Chou et al examined that both obese and non-obese type 2 diabetic 
patients showed decreased HbA1c after acarbose therapy. Obese patients had an 
additional benefit of a decrease in their previously elevated ALT and triglyceride 
levels. It usually have some beneficial effects on the elevated serum ALT levels in 
obese diabetic patients. In those with impaired glucose tolerance, it has been 
demonstrated to improve insulin secretion and insulin sensitivity.12 
 
          Tomomi Fujisawa et al suggested that 50 mg Acarbose and 0.3 mg Voglibose had 
similar overall effects on postprandial hyperglycemia as well as subjective symptoms, 
but marked inter individual variation will exist. Subjective symptoms may be a 
predictor of the divergent clinical response to each agent. It is also possible that 
postprandial hyper glycemia is affected by differences in the glycemic index of 
carbohydrates in the diet. The present results suggest the usefulness of subjective 
symptoms as a predictive marker for clinical efficacy of each agent, which is 
applicable for better management of diabetes mellitus.40 
       
   Chang-Yu Pan et al examined that Acarbose was efficacious and safe in the 
reduction of hyperglycaemia and hyperinsulinaemia in IGT subjects, indicating a 
potential benefit for the delay or prevention of onset of Type 2 diabetes. A low dosage 
  
 
of acarbose in the present study proved to be sufficient for the improvement of 
metabolic control and was well tolerated. It also adds evidence that pharmacological 
intervention with acarbose can be effective in Chinese IGT subjects. 41 
 
       H. Delgado et al reported that treatment with Acarbose is efficient even in 
diabetic patients presenting a good glucose control without any other associated 
treatment. By decreasing the elevated post prandial blood glucose, it improves both 
insulin sensitivity and insulin secretion. It usually allow a significant improvement in 
post prandial glycemic peaks in well controlled Type II diabetes patients. It disclose 
Acarbose efficacy as monotherapy in well controlled obese Type II diabetic patients.42 
 
      Shi-Dou Lin et al suggested that Acarbose - Metformin combination therapy is 
more effective in reducing intraday and interday glucose variability without 
increasing the duration of hypoglycemia compared with the Glibenclamide –
Metformin combination. Asian people typically consume a higher proportion of 
carbohydrates in their diet, and this reflects the more important role of postprandial 
hyperglycemia. Acarbose, as a result, may be an appropriate add-on drug for Type II 
diabetic patients inadequately controlled with Metformin alone.43 
 
      Lam K S et al examined that the use of Acarbose in moderate doses in NIDDM 
patients inadequately controlled on conventional oral agents resulted in beneficial 
effects on glycemic control, especially postprandial glycemia, and mean body weight. 
Additional use of acarbose can be considered as a useful alternative in such patients if 
they are reluctant to accept insulin therapy.44 
 
  
 
       O. Schnell et al investigated the effect of Acarbose in patients with type 2 
diabetes with newly initiated insulin treatment who had previously been insufficiently 
controlled with oral antihyperglycaemic agents. As adjunct administration to newly  
initiated insulin therapy, acarbose enhances the optimization of blood glucose control 
in patients with type 2 diabetes. 45 
 
N. Scorpiglione et al evaluated in their study an integrated evaluation of the 
overall effectiveness of acarbose in clinical practice. The benefits of the drug in an 
unselected population of non-insulin-dependent diabetes mellitus patients are 
significant but of marginal clinical relevance. Patients on long term treatment, 
particularly through possible postponement of secondary oral antidiabetic agent 
failure, will allow a reliable definition of the cost-effectiveness of this complementary 
component of anti-diabetic strategy. 46 
 
     Chan J C et al examined in an Asian multicenter clinical trial involving six ethnic 
groups, Acarbose 100 mg tid. was an effective, safe, and generally well-tolerated 
therapy in Type II diabetic patients with dietary failure. In some patients with 
troublesome gastrointestinal symptoms, a lower dosage may be necessary. Here the 
efficacy and tolerability of acarbose compared with placebo in Type II diabetic 
patients previously treated with diet .47 
 
       Rury R. Holman et al reported that Acarbose significantly improved glycemic 
control over 3 years in patients with established Type II diabetes. Careful titration of 
acarbose dose is needed in view of the increased noncompliance rate seen secondary 
to the known side effects. It is particularly useful as an alternative first-line treatment 
  
 
for type 2 diabetes, when diet alone is insufficient and targets postprandial 
hyperglycemia. This specific mode of action also means that acarbose can be 
combined successfully with other agents which primarily reduce fasting 
hyperglycemia. The lack of any deleterious effects with respect to clinical outcomes 
and the absence of effect on body weight are desirable features.48 
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PLAN OF THE STUDY 
 
 
      
       PHASES 
 
 
STEPS 
      
       ACTIVITY 
 
TIME PERIOD 
 
   PHASE 1 
 
 
 
STEP 1 
 
Identification of target areas 
for possible study 
 
June 2011 
 
 
STEP 11 
 
 
Literature survey June 2011 
 
 
 
STEP 111 Defining crieteria and 
standards 
July 2011 
 STEP 1V 
 
 
Designing of data collection 
form 
July  2011 
  PHASE 11 STEP V Collection of  data through 
patients case sheet and 
treatment chart 
July 2011-January 
2012 
  
 PHASE 111 
 
 
 
STEP V1 
 
Analysis of data 
 
January 2012 
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                                                     OVERVIEW 
 Diabetes mellitus is a heterogeneous group of disorders which occur secondary to 
various genetic predispositions and precipitating factors. It is characterized by 
disorders in carbohydrate, fat and protein metabolism and it occurs due to an absolute 
or relative deficiency of insulin and abnormally high amounts of glucagon and other 
counter regulatory hormones. In particular, rates of type 2 diabetes are rising in 
developing countries and are undergoing an epidemiological transition from 
communicable to chronic diseases.3 It usually affects more than 120 million people 
world-wide, and it is estimated that it will affect about 220 million by the year 2020. 
It is usually irreversible though patients can lead a reasonably normal lifestyle.49 
   It is a chronic disease and begins with an early asymptomatic phase characterised by 
insulin resistance, and progresses to postprandial hyperglycaemia and, eventually to 
overt type 2 diabetes. The principal metabolic defects in type 2 diabetes are insulin 
resistance, beta-cell dysfunction, and increased hepatic glucose production. The 
DCCT demonstrated that level of glycemic control will correlate the appearance and 
progression of retinopathy, nephropathy and neuropathy.10 
The two major classifications of DM are Type I and Type II. These were formerly 
known as Insulin Dependent and non Insulin Dependent Diabetes Mellitus. They 
differ in clinical presentation, onset, etiology and progression. Both are associated 
with microvascular and macrovascular complications. Diagnosis of diabetes is usually 
made by three crieteria:- 
 Fasting plasma glucose of ≥ 126mg/dl 
 A 2 hr value from a 75g oral glucose tolerance test of ≥ 200 mg/dl 
 
  
 
 A casual plasma glucose level of  ≥ 200 mg/dl  with symptoms of diabetes 50 
Type 1 has been considered as a disease of sudden onset but the development occurs 
as a slow process of progressive immunological damage. Obesity is considered as an 
important risk factor for it. Its associated with hyperinsulinaemia and marked insulin 
sensitvity.6 Diet therapy usually remains as the cornerstone of the treatment strategies 
for non-insulin-dependent diabetes mellitus. It aims to maintain ideal body weight and 
to reverse any metabolic abnormalities associated with the disease.  
 PPBS and elevations in HbA1C levels have been considered as the long term 
complications of diabetes. Not all patients respond adequately to diet, exercise, or 
treatment with oral drugs, alternate therapies have been investigated. Acarbose which 
is the first α-glucosidase inhibitor exerts its activity by reversibly inhibiting the 
enzymatic cleavage of complex carbohydrates to simple sugars which results in a 
reduction in PPBS and subsequently, reductions in HbA1c levels.51 
Type 1 treatment necessitates insulin therapy while the treatment of type 2 DM often 
necessiates use of multiple therapeutic agents including oral antihyperglycemics and 
insulin to obtain glycemic goals. Prevention strategies for type 2 DM are established 
which include lifestyle changes, dietary restriction of fat, aerobic exercise and weight 
loss.5 PPBS has been shown to be an independent cardiovascular risk factor. The 
properties of Acarbose makes it a promising agent for the treatment of patients 
presenting hyperglycemia, hyperinsulinemia and hypertension and attenuates PPBS.10 
                               
 
  
   
  
 
   Etiologic Classification Of Diabetes Mellitus 
1) Type 1 Diabetes (β cell destruction leading to absolute insulin deficiency) 
             a) Immune mediated 
        b) Idiopathic 
2) Type 2 Diabetes ( secretory defect with insulin resistance) 
3) Other specific types 
     a) Genetic defects of β cell function 
      b) Genetic defects in insulin action 
      c) Disease of the exocrine pancreas:-PancreatitiS, Neoplasia, Cystic fibrosis 
     d) Endocrinopathies :- Acromegaly, Cushing's syndrome 
        e) Drug or chemical Induced:- Nicotinic acid,  Glucocortecoids, Thiazides 
  f) Infections:-Congenital rubella, Cytomegalovirus 
g) Uncommon forms of immune mediated Diabetes:-Stiff-man syndrome, Anti 
Insulin Receptor Antibodies 
4) Gestational  Diabetes mellitus3 
 Etiology 
 Diabetes mellitus  has been associated with many etiological factors which includes 
obesity, increasing age, heredity, emotional stress, autoimmune β cell damage, 
endocrine diseases (cushings disease),vasculitis in tissues highly perfused with 
capillaries (eye, kidney), insulin receptor or post insulin receptor defects, drugs 
(cortecosteroids, thyroid drugs, thiazide diuretics).52  Type 1 has been widely believed 
to be a disease of clinically rapid onset but the development is related to a slow 
process of progressive immunological damage. Other factors that precipitate clinical 
diabetes may be caused by infection when β cells in the pancreas falls below 5-10%. 
  
 
One of the main cause of type 1 DM is autoantibodies directed against pancreatic islet 
which appears in circulation and predate the clinical onset. If one child in a family has 
type 1 diabetes, each sibling has a 6% risk of developing diabetes by age. 31 If siblings 
are HLA-identical, the risk rises to about 20%. Longer-term follow-up has shown that 
the lifetime risk of diabetes in first-degree relatives is considerably greater than this.10   
Type 2 diabetes has a strong genetic predisposition. If a parent has type 2, the risk of a 
child eventually developing type 2 is 5- 10 % compared with 1-2% for type. Mainly 
central obesity where subcutaneous fat is deposited intra abdominally is considered as 
the most risk factor.6 
Epidedmiology 
Diabetes mellitus is present in roughly 16 million citizens. Around 675000 people 
have type 1 and majority of those remaining have type 2 diabetes. Girls experience a 
peak incidence of type 1 between 10 and 12 years where as boys have higher 
incidence between 12 and 14 years. Diabetes in people older than 20 accounts for 90-
95 % of all cases.1 In the UK Prospective Diabetes Study (UKPDS) it has been shown 
that intensive glucose control significantly reduced the risk of microvascular 
complications by 25%.12 Type 1 DM accounts for upto 10% of all cases of DM and 
results from an autoimmune destruction of the pancreatic β cell. Type 2 DM  accounts 
for about 90% of all cases of DM.53 
Pathogenesis 
Type II DM 
Impaired insulin secretion and resistance to the action of insulin characterize patients 
with type 2 diabetes. In the presence of insulin resistance, glucose utilization by 
tissues is impaired, hepatic glucose production is increased, and excess glucose 
  
 
accumulates in the circulation. Type 2 diabetes is associated with a variety of 
disorders, including obesity, atherosclerosis, hyperlipidemia, and hypertension.54 
       Pathogenesis of Type II Diabetes Mellitus       
       
 
 
 
 
 
 
 
 
 
 
 
 
 
Signs and symptoms 
Type 1 diabetes usually presents typically with polydipsia, polyuria, polyphagia, 
weakness, weight loss, dry skin and ketoacidosis. Type 2 Diabetes typically is slow in 
onset and is often unaccompanied by symptoms. The different features include 
glucosusuria, proteinuria, micro aneurysms and retinal exudates. Other symptoms of 
 Genetic Predisposition 
 Multiple Genetic Defects 
Environment 
Primary Beta Cell Defect 
Peripheral Tissue Insulin Resistance 
Obesity 
Inadequate Glucose Utilization Deraged Insulin Secretion 
Hyperglycaemia 
Beta Cell Exhaution 
Osmotic Diuresis: 
 Polyuria 
 Polydypsia 
 Hypokalemia 
Glucosuria: Urine has high Specific 
Blood Glucose > Renal Threshold 
Hyperosmotic Plasma 
Dehydration of Cells 
Hyperglycemic Coma 
  
 
hyperglycemia include blurred vision, tingling or numbness of the extremities, skin 
infections, itching , drowsiness and irritability55 
 Microvascular complications   
These effects of hyperglycemia range from minor symptoms to life threatening 
metabolic complications. The two serious short term complications are:- diabetic 
ketoacidosis (DKA) and non ketotic hyperosmolar syndrome (NHKS). DKA is life 
threatening condition that usually occur secondary to an insulin deficit. It may occur 
in patients who have an active infection, those who have discontinued insulin therapy 
or those subjected to other forms of stress.21 
Retinopathy -  After 20 years from the onset of diabetes over 90% of people with 
type1 and over 60% of people with type II will have retinopathy.4 Early onset of 
retinopathy may be reversed with improved glycemic control. Laser photocoagulation 
has improved slight preservation in diabetic retinopathy.56 
Nephropathy - In diabetic renal disease the kidneys become enlarged and the 
glomerular filtration rate initially increases. The presence of nephropathy is indicated 
by the detection of microalbuminuria. If higher amounts of albumin are detected, its 
termed as proteinuria or macroalbuminuria. 
Peripheral Neuropathy - It’s the progressive loss of peripheral nerve fibres resulting 
in nerve dysfunction. It may lead to distal sensory symptoms which is evident in the 
feet. The manifestations of autonomic neuropathy are diabetic impotence, bladder 
dysfunction, gastroparesis and dry skin.57 
 Macrovascular disease 
  
 
The different macrovascular complications include cardiovascular disease (coronary 
heart disease and stroke) and peripheral vascular disease 
Cardiovascular disease:- Its one of the most common cause of death in patients with 
type 2 DM.. The different cardiovascular disease risk factors are smoking and 
dyslipidaemia. Silent MI is more common in diabetic patients and may be due to 
cardiac autonomic neuropathy 
Peripheral Vascular Disease:- It affects blood vessels outside heart. It often affects 
arteries of the legs and may give rise to intermittent claudication which is usually 
experienced on walking. The iliac vessels can also be affected and causes buttock pain 
and erectile dysfunction. 
Treatment 
Oral Hypoglycemic Drugs 
These drugs lower blood glucose levels and are effective orally 
 Sulfonyl Ureas - Tolbutamide, Chlorpropamide, Glibenclamide, Glipizide, 
Glimipride 
 Biguanides - Phenformin, Metformin 
 Meglitinide Analogues - Repaglinide, Nateglinide 
 Thiazolidinediones - Rosiglitazone, Pioglitazone 
 Alpha Glucosidase Inhibitors - Acarbose, Miglitol, Voglibose 
These drugs are indicated only in type II diabetes, when not controlled by diet and 
exercise.29 
 
 
  
 
InsulinTherapy  
Insulin is the mainstay for treatment of virtually all Type I DM and many Type II DM 
patients. When necessary, insulin may be administered intravenously or 
intramuscularly; however, long-term treatment relies predominantly on subcutaneous 
injection of the hormone.22 Insulin therapy may induce an increase in weight, worsen 
insulin resistance and have the possibility to contribute to macroangiopathic 
complications. 
Properties of currently available Insulin preparation  57 
TYPE APPEARANCE ZINC CONTENT, 
mg/100 units 
BUFFER ONSET PEAK DURATION 
Rapid 
Regularsoluble 
(crystalline) 
Clear 0.01-0.04 None 0.5-0.7 1.5-4 5-8 
Lispro Clear 0.02 Phosphate 0.25 0.5-1.5 2-5 
Aspart Clear 0.0196 Phosphate 0.25 0.6-0.8 3-5 
Glulisine Clear None None — 0.5-1.5 1-2.5 
Intermediate 
NPH (isophane) Cloudy 0.016-0.04 Phosphate 1-2 6-12 18-24 
Lente Cloudy  0.2-0.25 Acetate 1-2 6-12 18-24 
 Slow 
Ultralente Cloudy  0.2-0.25 Acetate 4-6 16-18 20-36 
Protamine zinc Cloudy  0.2-0.25 Phosphate 4-6 14-20 24-36 
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METHODOLOGY 
Objective: 
To study the long term efficacy of Acarbose in improving glycemic control in 
patients with Type II diabetes mellitus   
Study Design: 
It is a prospective observational study. 
Study Site: 
The study was conducted in the department of Diabetology, Kovai Medical 
Center and Hospital, a multispecialty hospital in Coimbatore, Tamilnadu. 
Study Period: 
           The study was conducted  from June to January  2012. 
Study Population: 
           Both male and female patients diagnosed as Type  II Diabetes Mellitus. 
                      Patients having glycosylated hemoglobin (HbA1C) above the upper limit (more 
than 6.5%) 
Sources of Data: 
           The data was collected from various sources such as patient’s case sheet, 
treatment chart, laboratory reports and also through direct patient interview. 
Study Procedure: 
In this prospective study both male and female patients diagnosed with Type II 
Diabetes mellitus having HbA1C value more than 6.5% were included and those 
  
 
having type 1 DM taking insulin as sole therapy and patients with chronic intestinal 
disease are excluded. All the patients who fulfill the inclusion crieteria are taken for  
the study. The laboratory values and medications are noted from the patient’s chart.  
 Values such as FBS, PPBS, HbA1C, BMI are noted at the initial visit and the 
therapeutic efficacy of the drug in reducing these parameters were determined during 
the next review. Acarbose was usually given in addition to the current diabetes 
medications. Another group was also included in the study where patients taking other 
oral hypoglycemic agents except Acarbose. The percentage reduction in blood 
glucose profile in both groups were calculated and the therapeutic efficacy of the drug 
was determined 
Data are collected from the data entry form which gives values of blood glucose 
profile. Baseline and review values were compared by paired students 't' test. The 
significant reduction produced in blood glucose value was determined. 
 
Also the percentage reduction in blood glucose profile produced by Acarbose in obese 
and non obese patients was also calculated. 
Data Analysis: 
Data will be analyzed by using Graph Pad Prism 5.04 software. Results were 
expressed as percentage, mean and standard deviation. The result of the study was 
analysed by paired ‘t’ test. All the test were two tailed Values of P<0.05 and P<0.01 
were considered statistically significant.   
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     Table: 1 Shows gender wise distribution among study population (n=74) 
 
                                            
                                                 Fig-1 Gender wise Distribution 
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S.No 
 
Gender 
 
Percentage of Patients 
 
1 
 
Male 
 
56.7 
 
2 
 
Female 
 
43.2 
 
  
 
Table: 2 Shows mean age and gender wise distribution among study population 
 
                
                                   Fig-2  Mean age and Gender wise Distribution 
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S.No 
 
Gender 
 
Age (mean±SD) 
 
1 
 
Male 
 
55.14±11.28 
 
2 
 
Female 
 
           54.3 ± 10.6 
  
 
 Table: 3 Shows categorization of body mass index among study population 
 
BMI Percentage of patients 
Obese(≥25) 72.9 
Non obese (<25) 27.02 
 
                      Fig-3 Categorisation of BMI among study population 
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Table: 4 Shows family history of Type II Diabetes among study population 
 
            
                 Fig- 4 Family History of Type II Diabetes among study population  
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Family History          Percentage of patients 
    Yes                        64.8 
     No                        35.1 
  
 
        
  Table: 5 Shows duration of diabetes among  study population 
 
                          Fig-5 Duration of Diabetes Among study population 
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S.No 
 
Duration of Diabetes 
 
Percentage  
 
1 
 
0-5 
 
22.9 
 
2 
 
                   6- 10 
 
39.1 
 
3 
 
                  11-15 
 
                    21.6 
 
4 
 
16-20 
 
10.8 
 
5 
 
21-25 
 
5.4 
  
 
         Table: 6 shows Past medical history among study population   
 
 S. no:             Past medical history             Percentage 
     1                Hypertension              60 
     2            Ischemic Heart Disease              20 
     3            Hypercholestrolemia             16.2 
     4            Reactive depression              9.4 
     5             Obesity             32.4 
     6            Hypothyroidism             18.9 
     7            Renal Impairment             29.7 
     8            Foot ulcer             43.2 
 
                   Fig-6   Past Medical History among Study Population 
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            Table: 7 Shows Social Habits among Study Poulation 
 
Smoking        Percentage Of Patients 
    Yes              67.5 
     No              32.4 
 Alcohol        Percentage Of Patients 
     Yes             59.4 
      No             40.5 
 
                          Fig-7 Social habits Among study population 
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                           Table: 8  Diet Habits Among Study Population 
 
        S.No             Diet Percentage of Patients 
      1         Diabetic 75.6 
      2         Non Diabetic 24.32 
 
                      
                                   Fig-8  Diet Habits Among Study Population 
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     Table : 9 Dose wise Distribution Of Acarbose Among Study Population 
 
     Sl NO: Prescribed Dose        
(Acarbose) 
Percentage Of Patients 
    1       25mg       48.64 
    2      50 mg        37.83 
    3     100 mg       13.51 
 
                     
                  Fig-9 Dose wise Distribution Among Study Population 
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Table : 10  Percentage Reduction In Blood Glucose Profile In Obese And  Non   
                     Obese Patients 
 
 S.No  Category Percentage Reduced Percentage Not 
Reduced 
    1    Obese         81.4 18.5 
    2   Non Obese          75 25 
 
                        Fig-10 Percentage Reduction in blood glucose profile 
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Table:11 shows Combination Of Acarbose With Other Antidiabetic Drugs 
 
     S. No        Drugs      Percentage 
              1 Acarbose + OralHypoglycemics 45.7 
              2 Acarbose + Insulin 34.2 
               3 Acarbose + Oral Hypoglycemics + 
Insulin  
20 
 
            
              Fig-11 Acarbose in combination with other antidiabetic drugs 
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Table: 12  Shows Percentage  Reduction in FBS in Acarbose Treated Group 
                                         and Group Without Acarbose 
 
              S. No        Drugs  Percentage  Reduction 
                  1  Oral Hypoglycemics              9.37 
                  2  Acarbose +Oral hypoglycemics             17.65 
                  3 Acarbose + Oral Hypoglycemics 
+ Insulin 
            18.80 
 
                     Fig-12  Percentage reduction of FBS In each Study Group 
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Table : 13 Percentage Reduction In PPBS in Acarbose treated group and in 
group without Acarbose 
 
S.No                     Drugs Percentage Reduction 
 
1 
         
  Oral Hypoglycemics 
 
                 6.10 
 
2 
 
Acarbose + OralHypoglycemics 
                 
                 16.05 
 
3 
 
Acarbose + OralHypoglycemics 
+ Insulin 
 
16.82 
 
                    Fig-13 Percentage Reduction in PPBS in each study group 
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Table: 14 shows Percentage Reduction In HbA1C  in Acarbose treated group and  
                                                  in group without Acarbose  
 
       S.No                           Drugs Percentage Reduction 
           
          1 
 
Oral Hypoglycemics 
    
          5.51 
        
           2 
  
Acarbose + Oral Hypoglycemics 
    
         14.95 
             
           3 
 
Acarbose + Oral Hypoglycemics + 
Insulin 
     
          17.92 
 
             Fig-14 Percentage Reduction in HbA1C in each study group 
5.51
14.95
17.92
0
2
4
6
8
10
12
14
16
18
20
Oral hypoglycemics Acarbose+ Oral
Hypoglycemics
Acarbose+ Oral
Hypoglycemics+
Insulin
Drugs
Pe
rc
en
ta
ge
 R
ed
uc
tio
n
 
      
 
  
 
Table – 15: shows t test for the mean difference between baseline and review values  
of  FBS in each group of patients 
     
     Drugs 
 
Baseline FBS value 
(mean±SE)mg/dl 
 
FBS at  Review 
(mean±SE)mg/dl 
 
FBS Reduction 
(mean ±SE)mg/dl 
 
p value 
 Oral hypo 
glycemic drugs 
     169.96 ± 5.69  162.88± 5.87 
 
  7.08 ± 3.18 
 
0.034* 
 
Acarbose + Oral 
Hypoglycemics 
 
   171.75 ± 10.54 
 
157.63± 38.65 
 
   14.12 ± 8.51 
 
0.117 
Acarbose + Oral 
Hypoglycemics 
+ Insulin 
 
     173.47± 8.70 
 
 146.21±10.32 
 
   27.26± 6.57 
 
0.0006** 
 
 
 Table – 16 shows 't' test for the mean difference between baseline and review values 
of PPBS in each group of Patients  
 
           Drugs 
 
Baseline PPBS value 
(mean± SE)  mg/dl 
 
PPBS at review 
(mean± SE) mg/dl 
 
PPBS Reduction 
(mean± SE) mg/dl 
 
p value 
Oral hypoglycemic 
drugs 
264.73± 10.29 
 
262.08± 9.18 
 
2.65 ± 3.73 
 
0.484 
Acarbose + Oral 
hypoglycemics 
263.87 ± 22.16 
 
223.75 ± 16.86 
 
40.12 ± 15.25 
 
0.018* 
Acarbose + Oral 
Hypoglycemics + 
Insulin 
283.42± 16.34 241.58± 16.37 
 
41.84±11.81 
 
0.002** 
 
 
  
 
Table-17: shows t test for the mean difference between baseline and review  
values of  HbA1C   in  each group of patients 
 
 
      Drugs 
 
Baseline HbA1C 
value (mean± SE) 
mg/dl 
 
HbA1C value at 
review (mean± 
SE) mg/dl 
 
HbA1C Reduction 
(mean± SE) mg/dl 
 
 p value 
Oral 
hypoglycemics 
9.17 ± 0.24 9.12 ± 0.19 
 
0.05 ± 0.11 
 
0.692 
Acarbose + Oral 
hypoglycemics 
8.9 ± 0.80 7.76 ± 0.53 
 
1.14 ± 0.37 
 
0.0007* 
Acarbose + Oral 
Hypoglycemics 
+ Insulin 
8.31 ± 0.49 7.07 ± 0.77 
 
1.24 ± 0.48 
 
0.043** 
 
 
Table-18: shows t test for the FBS reduction in Obese and Non Obese patients 
 
S.No Category Baseline FBS 
value (mean±SE) 
FBS at review 
(mean± SE) 
FBSReduction 
(mean± SE) 
   p value 
 
    1 
 
Obese 
 
177.59 ± 9.05 
 
 
144.26 ± 8.29 
 
 
33.33 ± 8.41 
 
 
0.0005** 
 
     2 
 
Non Obese  
 
168.25±13.65 
 
 
152.25±10.29 
 
 
16 ± 12.59 
 
 
0.244 
 
 
 
  
 
Table-19: shows 't' test for the PPBS reduction in obese and non obese patients 
S.No Category Baseline PPBS 
value 
(mean±SE) 
PPBS at review 
(mean±SE) 
PPBS Reduction 
(mean± SE) 
   p value 
  1 Obese 
 
271.26± 15.67 225.74± 14.04 
 
45.52 ± 11.58 
 
0.0006** 
 
2 
 
Non Obese 
 
 
284.88 ± 26.41 
 
259.38 ± 17.50 
 
 
25.5 ± 10.98 
 
0.0532 
  
  
 
Table -20:  shows  't' test for HbA1C Reduction in obese and non obese patients 
S.No Category Baseline 
HbA1C value 
(mean± SE) 
HbA1Cat review 
(mean ± SE) 
HbA1C reduction   
(mean± SE) 
  p value 
 
1 
 
Obese 
 
     8.96±0.38 
 
 
7.71± 0.39 
 
 
1.25 ± 0.25 
 
 
<o.ooo1** 
 
2 
 
 
Non Obese 
      
    8.07±0.85 
 
7.41 ± 0.65 
 
0.66 ± 0.30 
 
 
0.03* 
 
 
 
 
 
  
 
 
 
 
 
 
 
Results 
 
 
 
 
 
 
  
 
 
RESULTS 
The study was carried out at Kovai Medical Center and Hospital. A total of  74 Type 
II diabetic patients who visited the outpatient diabetic department of the hospital were 
included in our study. Out of which 40 patients were on Acarbose therapy and 34 
patients were in another group taking  oral hypoglycemic agents except Acarbose. In 
Acarbose treated group 35 patients came for review after a  duration of 3 months and 
in the other group 26 patients came for review.   
The demographic details among the subjects reveals that 42 (56.7) were males while 
59 (43.2) were females {Table:1}. The mean age of the total population was 54.77 ± 
9.60. The mean age of males and females were 55.14 ± 11.28 and 54.3 ± 10.6 
respectively {Table:2}. From the past medical history hypertension was detected in 45 
(60.14%) patients, Ischemic heart disease in 15 (20.06%), Hypercholestrolemia in 12 
(16.2%), reactive depression in 7(9.4%),  obesity in 24 (32.4%), renal impairment in 
40 (29.7%) and foot ulcer in 58(43.2%).{Table:6} Distribution of patients evaluated 
as obese and non obese with respect to their body mass index was established as 
72.9% and 27.02% respectively {Table: 3} 
Family history of type II Diabetes mellitus was present in 48 (64.8%) and 26 (35.1%) 
had no history of diabetes mellitus. {Table:4}.Patients data were collected about their 
smoking habits and 67.5% were found to be smokers and 32.4% were found to be non 
smokers. Alcohol history of the study population was collected, out of this (59.4%) 
were found to be alcoholics and (40.5%) were non alcoholics.{Table:7} 
  
 
Concerned with the duration of diabetes 17 (22.9%) had an experience of 0-5 years, 
29 (39.1) had 6-10 years, 16 (21.6) had 11-15 years, 8 (10.8) had 16-20 years, and 4 
(5.4) had 21-25 years of experience. {Table:5}. On considering the diet habits among 
the study population 56 (75.6%) patients were on diabetic diet and 18 (24.32%) were 
on non diabetic diet. {Table:8}. Age wise distribution of patients taking Acarbose 
among the study group were 6 (8%) in 30-39 years, 17 (23%) in 40-49 yrs, 22 (30%) 
in 50-59 years and 29 (39%) patients were in the age group of 60-69 years. 
The different dose wise  distribution of Acarbose among the study population were 
25mg, 50mg and 100mg and the percentage of patients using different doses were 
48.64%, 37.83% and 13.51%.{Table:9} Out of 40 patients on Acarbose therapy 35 
came for review after  duration of 3 months and 5 patients were considered as non 
respondents Based on their BMI they were classified as  27 (77.14%) as obese and 8 
(22.8) as non obese. The percentage reduction of blood glucose level  in each group of 
patients were done and it was found out that (81.4%) was reduced in obese patients 
and (75%)  in non obese patients{Table:10} 
The study population consisted of two groups where patients taking Acarbose was 
included in group I and patients taking other oral hypoglycemic agents were included 
in the group II. It was again divided into three groups where patients taking  oral 
hypoglycemic agents except Acarbose was group I, Acarbose with oral hypoglycemic 
agents was group II, Acarbose with combination of oral hypoglycemic and Insulin 
considered as group III  and the percentage reduction in FBS, PPBS and HbA1C 
produced in each group were calculated .  
  
 
The percentage of  patients taking other oral hypoglycemics were 26 (76.4%), 
Acarbose with oral hypoglycemics were 16 (45.7%), Insulin 12 (34.2%) and 
combination of oral hypoglycemics and Insulin were 7 (20%). {Table:11} 
The mean difference between baseline and review values of FBS, PPBS and HbA1C 
in each group of study population ie obese and non obese were measured and the 
significant difference produced were compared by paired students t test. The baseline 
value of FBS  in obese patients was found to be 177.59 ± 9.05 and for non obese 
patients it was found to be 168.25 ± 13.65. The review values in each group of 
patients was found to be respectively 144.26± 8.29 and 152.25 ± 10.29.The P value 
for obese patients were 0.0005 which is considered as highly significant and for non 
obese patients it was 0.244 which is not significant. {Table: 18} 
 The baseline value of PPBS in obese patients was found to be 271.26 ± 15.67 and in 
non obese patients the value was found to be 284.88 ± 26.41. The review values for 
both obese and non obese patients were found to be 284.88 ±26.41 and 259.38 ± 
17.50. The P value for obese patients were 0.0006 which is highly significant and for 
non obese patients it was 0.0532 which is not significant. {Table:19} 
 The baseline value of HbA1C in obese patients was found to be 8.96±0.38 and in non 
obese patients the value was 8.07±0.85. The review value in both these groups were 
found to be 7.71± 0.39 and 7.41 ± 0.65. The P value in case of obese patients were 
found to be <0.0001 which is considered as highly significant and for non obese 
patients it was 0.03 which is also significant. {Table:20} 
Again the study population was divided into three groups where Acarbose was given 
in combination with other antidiabetic drugs such as oral hypoglycemics, Insulin and 
combination of oral hypoglycemics and Insulin. The mean difference in FBS, PPBS 
  
 
and HbA1C in these three groups were measured and the significant difference 
produced were compared by pared students t test.  
The baseline value of FBS in these three study groups were found to be respectively 
169.96 ± 5.69, 171.75 ± 10.54 and 173.47 ± 8.70. The review values of FBS in these 
three groups were found to be 162.88 ± 5.87, 157.63 ± 38.65 and 146.21 ±10.32. The 
P value for first group, oral hypoglycemic agents were  found to be 0.034 which was 
significant, the second group ie combination of Acarbose and oral hypoglycemic 
agents were found to be 0.117 which is not significant. The P value for the third group 
where Acarbose was given in combination with oral hypoglycemics and Insulin was 
found to be 0.0006 which is highly significant. {Table:15} 
The baseline value of PPBS in three group of patients were found to be 264.73 ± 
10.29, 263.87 ± 22.16 and 283.42 ± 16.34. The review values in each group of 
patients were found to be 262.08± 9.18, 223.75 ± 16.86 and 241.58± 16.37. The p 
value for first  group was 0.484 which was not significant. The p value for second and 
third group were found to be 0.018 and 0.002  which is highly significant.{Table: 16}   
The baseline values of HbA1C in the three group of patients were found to be 9.17 ± 
0.24, 8.9 ± 0.80 and 8.31 ± 0.49. The review values in each study group was found to 
be 9.12 ± 0.19, 7.76 ± 0.53 and 7.07 ±0.77. The p value for the first group was found 
to be 0.692 which was not significant and the p value for the other two groups were 
found to be 0.0007 and 0.043 which was considered to be highly significant. 
{Table:17} 
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DISCUSSION 
 The prevalence of Diabetes mellitus is reported to be 6% of world's population in few 
studies1 and age related prevalence was found to be 8.4% in men and 7.9% in women. 
The prevalence and incidence of type II diabetes is rising rapidly with Asia and Africa 
having the greatest potential increases.8 Efficacy of α- glucosidase inhibitor Acarbose 
has been confirmed in more than 350 studies involving more than 30,000 patients. It 
was shown to be efficacious and have an excellent safety profile with minimal drug 
interactions. It is currently the only oral antidiabetes agent approved for the treatment 
of both prediabetes and Type II diabetes.49 In our study the percentage of patients 
taking Acarbose was found to be higher in males (56.7%)   than females (43.2%). The 
mean age distributions of our study population for male and female subjects were 
found to be 55.14 ±11.28 and 54.3 ± 10.6 respectively.  
There is increased risk of hypertension in Diabetes mellitus patients, being compatible 
with our finding was 6% and treatment with Acarbose showed improved glycemic 
control in hypertensive diabetic patient. P.Rosenbaum et al have reported that half of 
all diabetic patients are hypertensive and 64% of patients showed a reduction in 24-hr 
systolic BP and 0.8% reduction in HbA1C was obtained.30  
Cardiovascular disease, a comorbid disease was found to be 20% and treatment with 
Acarbose significantly reduced the macrovascular complications with significant 
cardiovascular benefits. Peter N Bavenholm have shown that cardiovascular disease 
  
 
accounts for upto 80% of death in patients with diabetes and intensive glucose control 
significantly reduce the macrovascular complications by 25%.36 
 Henrick Wagner et al have reported 48 of 62 type 2 diabetic patients patients 
(77.4%) as having cardiovascular disease in the study population.38 We detected 
cardiovascular disease in thyroid disorders in 18.9% and renal disease in 29.7 % of 
our study population. 
The study revealed that Acarbose was found to be a safe and tolerable drug and no 
serious adverse events could be linked to that drug but only few gastrointestinal 
symptoms were related to the drug. It caused flatulence in (20%) diarrhea in (11.4%) 
and (5.7%) patients reported of hypoglycemia. Jean- Louis Chiasson et al has found 
similar results in their study that Acarbose dose as large as 200mg had no toxic effect 
or serious adverse events and only gastrointestinal symptoms could be related. 
Compared with placebo, it was more frequently associated with flatulence (73.2%), 
diarrhea (43.6%) and abdominal cramps and discomfort was found to be 25%.16 
The study revealed that Acarbose was more effective in obese Type II diabetic 
patients than non obese patients. The prevalence of obesity in this study was high. 
Obesity is a disorder and it results from a complex interplay of environmental and 
genetic factors which is associated with significant morbidity and mortality. It plays a 
major role in the development of the metabolic syndrome, which consists of insulin 
resistance, diabetes, hypertension, and dyslipoproteinemia.7  In our study obese 
patients were found to be higher and showed a percentage reduction of 81.4% and 
75% in non obese patients. 
 S.Halmi et al in their study also showed the same result. It has been found that 
Acarbose significantly improved the metabolic profile of overweight patients with 
  
 
Type II diabetes who had inadequate glycemic control. The potential of Acarbose to 
delay the need for exogenous Insulin, in addition to producing statistically significant 
decrease in HbA1C, FBS and PPBS support its use for improving day to day 
metabolic control. Here Acarbose treated group had 0.9% decrease in HbA1C and it 
was associated with 25% reduction in the risk of microvascular endpoints.59 
 In our study it have been found that BMI did not showed a significant difference in 
obese and non obese patients before and after Acarbose treatment. It is usually 
calculated by dividing weight (in kilograms) by square height (in meters). It correlates 
significantly with body fat, morbidity, and mortality and can be calculated quickly 
and easily.7 The total review patients including both obese and non obese showed 
significant difference. Chien- Wen Chou et al in their study showed the same results. 
Here obese patients change in BMI were considered  not significant and non obese 
patients change in BMI showed a p value of (p= 0.0579).But the total patients had a 
significant decrease in body weight after treatment which showed a p value of <0.05 
which is considered as highly significant. 12 
In our study it has been shown that obese patients showed significant reduction FBS, 
PPBS and HbA1C.  (P value of 0.0005, 0.0006 and <0.0001). In case of non obese 
patients FBS and PPBS didn’t showed a significant result but HbA1C showed 
significant difference. Chein –Wen Chou et al in their study suggested that both 
obese and non obese patients showed significant differences in FBS,PPBS and 
HbA1C.All the parameters in obese patients and non obese patients showed a 
significant P value.12 
From the study which we have done it showed significant reduction  in FBS, PPBS 
and HbA1C when Acarbose was combined with other antidiabetics. The study 
  
 
population was divided into three groups where patients on oral hypoglycemic agents 
alone was considered as one group and  patients taking combination of Acarbose with 
oral hypoglycemics was second group and the third group consist of both oral 
hypoglycemics and Insulin. Monotherapy using Acarbose was not seen in any of the 
patients. The p value for FBS in the first two groups were found to be not significant 
but in the third group it was found to be significant. The values of PPBS in the first 
group was 0.484. In the second and third group it was significant (p=0.018) and 
(p=002).. The p value of HbA1C in the first group was 0.692 which was not significant 
and in the other two groups 0.0007 and 0.043 which were highly significant.  
L.Saniorgio et al in their study revealed the significant reduction  produced in blood 
glucose values when Acarbose was added to the current medications. Here the study 
population was divided into two groups. Group I consist of patients taking 
combination of Acarbose with oral hypoglycemics. Group II consist of patients 
undergoing treatment with Insulin alone or in combination with oral hypoglycemics. 
The P value of the three parameters in Group I were found to be <0.004, <0.0005 and 
<0.05.Similarly the P values in Group II was found to be <0.004, <0.0006 and <0.02. 
When Acarbose was stopped the blood glucose values increased.28 
Boniface. J. Lin et al conducted a study to assess the efficacy of Acarbose in Asian 
patients. It concluded that Acarbose is generally efficacious in reducing HbA1c levels 
irrespective of which concomitant therapy such as diet, sulfonyl ureas or combination 
of antidiabetic drugs. It also states that PPBS were reduced significantly in Acarbose 
treated group. Thus it provides a useful tool in the reduction of macrovascular com 
plications development.8 
  
 
 
 
 
 
 
 
Conclusion 
 
 
 
 
 
  
 
 
CONCLUSION 
Diabetes mellitus is a clinical syndrome characterized by hyperglycemia due to 
absolute or relative deficiency of insulin. Type II diabetes is a complex condition 
because there is a combination of insulin resistance together with impaired pancreatic 
beta cell function and thus leads to relative insulin deficiency. The different factors 
which may contribute to type II DM are greater longevity, obesity, unsatisfactory diet, 
sedentary life style and increasing urbanization. Acarbose is the first α glucosidase 
inhibitor that acts in the gastro intestinal tract and it has got wide margin of safety 
profile and low incidence of side effects. 
 
It represents a new approach to the management of NIDDM thus modulating gastro 
intestinal carbohydrate metabolism to control post prandial hyperglycemia and to 
maximize the long term glycemic control. Our study was focused on evaluating the 
therapeutic efficacy and tolerability of Acarbose in Type II diabetic patients in a 
clinical practice setting in an Indian population. It was found that mainly obese 
patients with elevated blood glucose profile have reduced blood glucose value with 
Acarbose polytherapy. Thus it has been more effective in reducing the blood glucose 
profile in obese patients as compared to non obese patients .  
 
 The different doses of Acarbose which prescribed were 25mg, 50mg and 100mg. 
Patients on oral hypoglycemic agents showed significant reduction in FBS while 
patients on  Acarbose therapy showed significant reduction in PPBS and HbA1C. No 
  
 
systemic side effects were observed and only few gastrointestinal side effects such as 
abdominal flatulence and loose stools were reported. 
 
From this study it has been concluded that Acarbose can be safely combined with 
other antidiabetic drugs such as oral hypoglycemic agents and Insulin. It was found to 
be safe and well tolerated due to its non systemic mode of action. It was also found 
that Acarbose in combination with oral hypoglycemics and Insulin was effective in 
reducing the PPBS and HbA1C than oral hypoglycemic agents alone used. 
 
Our study is a short term study involving only a small number of study population. 
Hence in the future controlled long term studies involving large number of patients 
are still needed to be carried out to evaluate if the advantages of addition of Acarbose 
are persistent and whether it is possible to obtain a reduction in vascular 
complications and mortality. 
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Annexure 
 
 
 
 
 
 
 
       
 
 
 
                                            
 
  
 
DATA ENTRY FORM 
 SL NO:-            Date of admission:- 
OP / IP No:-  .……………………… Age: …........Years          Sex: Male/Female 
 
 Name:-    
 
 Ht:-                   Wt:- 
  
Address :-                                                                                                                  
 
BMI:-
Occupation:-_ _ _ _ _ _ _ _ _        Family History:-  Yes/ No                 BP:- …………… mm Hg 
 
Duration Of Diabetes:-                Other Complications :-                           Diet:-    Veg/ Non 
Veg 
Social  Habits:                                             
                                      Smoking             Alcohol             Pan/ Hans            Tea/ Coffee    
Chief Complaints  
  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _   
 Examination 
_ _ _ _ _ _ _ _ _ _ _ _ _ _  _ _ _ _ _ _ _ _ _ _ _ 
_ _ ________________ _ _______________                                                 
_ _ _ _  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ 
Past Medical History:- 
…………………………………………………………. 
…………………………………………………………… 
……………………………………………………………. 
……………………………………………………… 
Past Medication History 
……………………………………………………… 
……………………………………………………… 
……………………………………………………… 
………………………………………………………. 
  
 
 
     ALLERGY                                            ⃞  YES                                      ⃞  NO 
                                           MONITORING PARAMETERS        
           Parameters      Baseline        After Review 
 
1) FBS 
2) RBS 
3) PPBS 
4) HbA1C 
5) BMI 
6) BP 
7) CHOLESTEROL 
8) TRIGLYCERIDES 
9) LDL 
10) HDL 
  
 
 
 
 
 
                            CURRENTLY PRESCRIBED DRUGS AND DOSAGE 
          
                Drugs 
      
       Dose 
 
       Frequency 
 
 
 
 
 
 
 
 
  
 
 
 
